SCHEMBL16769737

SCHEMBL16769737

COc1ccc(N2CCC(C(C)=O)CC2)nn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HRH3 Q9Y5N1 2/20 0.55
LMNA P02545 2/20 0.50
HTT P42858 1/20 0.50
KDM4E B2RXH2 6/20 0.46
TACR3 P29371 3/20 0.46
LCAT P04180 1/20 0.43
POLB P06746 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HPGD P15428 4/20 0.42
MAPT P10636 4/20 0.42
GLS O94925 1/20 0.41
CASP1 P29466 3/20 0.41
HSD17B10 Q99714 3/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
CASP7 P55210 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321187 0.88 LMNA (0.65) MEN1KMT2ASMN1; SMN2HRH3LMNA
SCHEMBL16769734 0.86 HRH3 (0.48) MEN1KMT2ASMN1; SMN2HRH3LMNA
SCHEMBL322942 0.82 MEN1 (0.56) MEN1KMT2ASMN1; SMN2HRH3LMNA
SCHEMBL12639925 0.81 LMNA (0.76) MEN1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL16769730 0.80 HRH3 (0.57) MEN1KMT2ASMN1; SMN2HRH3LCAT
SCHEMBL2005961 0.79 MEN1 (0.52) MEN1KMT2ASMN1; SMN2HRH3LMNA
SCHEMBL30790709 0.78 HRH3 (0.50) MEN1KMT2ASMN1; SMN2HRH3LMNA
SCHEMBL9219556 0.78 HRH3 (0.50) MEN1KMT2ASMN1; SMN2HRH3LMNA
SCHEMBL16769739 0.77 CHRNB2 (0.54) LCATMAPT
Hydrochloric Acid SCHEMBL2004943 0.77 HRH3 (0.49) MEN1KMT2ASMN1; SMN2HRH3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 MEN1 4861/4885KMT2A 1626/4885SMN1; SMN2 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.